Indiana life sciences companies rethink innovation
Research and development comes under pressure in an age of austerity.
BioCrossroads
Articles
Life sciences hold up in recession
A new report shows Indiana’s life sciences companies performed better than their peers around the country—and far better than the rest of Indiana’s private sector—during the early phases of the economic downturn.
BioCrossroads launches second seed fund
BioCrossroads Inc. has raised an $8.25 million seed fund in its second attempt to help startup life sciences companies grow to the point where they can attract venture capital or a corporate funder.
BioCrossroads has stoked state’s life sciences industry, but challenges remain
In the 10 years BioCrossroads has been promoting life sciences in Indiana, the effort has netted more than 330 new companies, an infusion of more than $330 million in venture capital, a tripling of exports, and a growing number of mentions in national reports on life sciences.
Health care VC hits new Indiana low in 2011
Indiana companies landed just $14.1 million in venture funding last year, the lowest amount of capital flowing to the state’s health care sector since BioEnterprises began tracking such deals in 2005.
Indiana’s medical device workforce will need skills upgrade
A new report by BioCrossroads says 53 percent of the 20,000 jobs in Indiana’s medical-device sector require no more than a high school education.
BioCrossroads seeds upstart medical device maker
BioCrossroads’ Indiana Seed Fund has invested $300,000 in a startup company chaired by a former Eli Lilly and Co. executive developing an absorbable stent.
Biocrossroads lands $2.8 million Lilly Endowment grant
The advocate for the state’s life sciences industry has now pulled in more than $25 million from the endowment.
Indiana life sciences leaders look toward the future
Former Eli Lilly and Co. vice president Richard Dimarchi, BioCrossroads President David Johnson, angel investor Oscar Moralez and Purdue University Senior Vice President Alan Rebar discuss issues ranging from the depth of the life sciences industry in Indiana to venture capital and Purdue’s Discovery Park.
More life sciences firms opt to launch products in Europe
The U.S. Food and Drug Administration’s growing reputation for unpredictability is spurring some Indianapolis companies to join counterparts elsewhere and introduce products in Europe. The upshot is that some Americans may never benefit from innovations occurring in their backyards.
Tech district could boost Indianapolis’ convention business
The Indianapolis Convention & Visitors Association plans to attract more life sciences conferences.
Report: State’s life science sector continues to grow
A total of 220 life sciences startups have been launched in Indiana since 2004, or an average of 44 per year, according to a new report from BioCrossroads that tracked the industry’s growth over the last eight years.
Lilly licenses Xigris rights to new biotech firm
Eli Lilly and Co. has agreed to license the U.S. marketing rights of its slow-selling sepsis drug Xigris to a newly created local biotech company called BioCritica that will seek to reinvigorate sales of the medication.
BISHOP: Warsaw’s orthopedics whizzes will master biologics
Industry cluster in northern Indiana has adapted to every other change in health care, and will absorb tissue regeneration, too.
Indianapolis bio sector hopeful as venture firms cash out
Profits flowing from earlier investments could mean more available capital, but firms continue to be selective in placing their bets.
Marcadia Biotech principals ponder next course
Marcadia execs French, Hawryluk reflect on massive growth of Carmel firm after sale to Roche.
Franciscan’s electronic records rollout shows industry growth
Franciscan Alliance will spend more than $100 million over the next two years to install a common electronic medical record system at its 13 hospitals and more than 165 physician practices. It’s a sign of the growth of the health information technology industry in Indiana, which a new BioCrossroads report says generates $200 million a year in sales and is growing at 8 percent annually.
Roche acquires Marcadia Biotech
Marcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in 2006, has been acquired by Swiss life sciences giant Roche.
Indiana Seed Fund makes 11th investment
A $250,000 investment in Aarden Pharmaceuticals will go toward advancing tuberculosis therapy through the pre-clinical development stage.
Lilly Endowment gives $35M to start pharmacy school
Manchester College will use money to launch the state’s third program offering doctorates in pharmacy.